UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) Delaware 27-5411038 (State or other jurisdict ...

Personalis, Inc. (NASDAQ:PSNL) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET Company Participants Caroline Corner - Investor Relations John West - President and CEO Aaron Tachibana - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Max Masucci - Cowen Mark Massaro - BTIG Mike Matson - Needham & Co. Kevin DeGeeter - Oppenheimer Sean Lee - H.C. Wainwright Operator Good day, ladies and gentlemen. And welcome to the Personalis First Quarter 2022 Earnings Conference Call. At ...

Financial Performance - Revenue for Q1 2022 was $15,227,000, a decrease of 27% compared to $20,881,000 in Q1 2021[123] - The net loss for Q1 2022 was $28,209,000, compared to a net loss of $12,404,000 in Q1 2021, representing a 128% increase in losses[123] - Total revenue for the first quarter of 2022 was $15.2 million, a decrease of 27% compared to $20.9 million in the same period of 2021[125] - Revenue from VA MVP decreased by $9.7 million to $3.5 million, a decline of 73% year-over-year, while revenue from all other customers increased by 53% to $11.7 million[125][126] - Total costs and expenses increased by 30% to $43.5 million in Q1 2022, compared to $33.4 million in Q1 2021[130] Expenses - Cost of revenue for Q1 2022 was $10,949,000, down from $13,454,000 in Q1 2021, reflecting a 19% decrease[123] - Research and development expenses increased to $17,098,000 in Q1 2022, up 80% from $9,496,000 in Q1 2021[123] - Selling, general and administrative expenses rose to $15,486,000 in Q1 2022, compared to $10,421,000 in Q1 2021, marking a 48% increase[123] - Research and development expenses rose by 80% to $17.1 million, primarily due to new service and product development and increased hiring[132] Cash and Investments - Cash and cash equivalents, along with short-term investments, totaled $266.5 million as of March 31, 2022, down from $287.1 million at the end of 2021[138] - The company incurred a net loss of $28.2 million in Q1 2022, with cash used in operating activities amounting to $11.4 million[143] - As of March 31, 2022, the company had cash and cash equivalents of $91.6 million and short-term marketable debt securities of $175.0 million[157] - The company plans to seek additional funding through equity offerings or debt financing if cash flow from operations is insufficient to meet liquidity requirements[140] Capital Expenditures - Capital expenditures are expected to be between $50 million and $55 million in 2022, primarily for facility renovations and laboratory equipment[148] Revenue Sources - The cumulative value of task orders from the VA MVP is approximately $186 million, with $181.6 million recognized as revenue as of March 31, 2022[105] - Revenue from Natera, Inc. contributed $3.9 million to the increase in revenue from all other customers, driven by strong demand for NeXT Platform services[128] - The company anticipates that revenue from all other customers will constitute the majority of total revenue in fiscal year 2022[129] Operational Capacity - The company has sequenced over 250,000 human samples, including more than 150,000 whole human genomes[104] - The company has the capacity to sequence and analyze approximately 200 trillion bases of DNA per week, which is larger than most cancer genomics companies[104] - The company plans to focus primarily on cancer, given the strong growth experienced in this sector in 2021 and early 2022[106] Headquarters and Expansion - The new headquarters in Fremont, California, will support expansion in laboratory capacity and research and development efforts[107] Financial Policies - There have been no material changes to the company's critical accounting policies and estimates compared to the previous fiscal year[154] - The company’s critical accounting policies include revenue recognition, stock-based compensation, and leases, which have the greatest potential impact on financial statements[153] - The company’s financial statements are prepared in accordance with U.S. GAAP, requiring estimates and assumptions that may differ from actual results[152] Interest Rate and Currency Risk - A hypothetical 100 basis point increase in interest rates would result in an approximate $0.9 million decline in the fair value of marketable debt securities[157] - The company does not enter into investments for trading purposes and has not used derivative financial instruments to manage interest rate risk exposure[158] - The majority of the company's revenue and expenses are transacted in U.S. dollars, with minimal impact from foreign currency movements to date[159] Customer Deposits and Loans - Customer deposits amounted to approximately $3.4 million as of March 31, 2022, with $2.8 million from a single customer[151] - The company entered into two noninterest bearing loans totaling $5.6 million for the purchase of computer hardware and software, with payments of $1.86 million due in 2022 and 2023[151]

Advanced Genomics Platform for Next-Generation Cancer Therapies Investor Presentation February 2022 Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this presentation, including statements as to future results of operations, financial condition, business strategy, plans, ...

Personalis, Inc. (NASDAQ:PSNL) Q4 2021 Earnings Conference Call February 24, 2022 5:00 PM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Kevin DeGeeter – Oppenheimer Patrick Donnelly – Citi Stephanie Yan – Cowen Joseph Conway – Needham Arthur He – H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Personalis Fourth Quarter and Full Year 2021 Earnings ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38943 Personalis, Inc. (Exact name of Registrant as specified in its Charter) Delaware 27-5411038 (State or other jurisdiction of incorporation ...

Personalis, Inc. (NASDAQ:PSNL) Q3 2021 Earnings Conference Call November 4, 2021 8:30 AM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Neel Ram – Morgan Stanley Kevin DeGeeter – Oppenheimer Patrick Donnelly – Citi Arthur He – H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Personalis Third Quarter 2021 Earnings Conference Call. At this time, all ...

For the quarterly period ended September 30, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) Delaware 27-5411038 (State or other juri ...

Advanced Genomics Platform for Next-Generation Cancer Therapies Personalis® Investor Presentation August 2021 Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this presentation, including statements as to future results of operations, financial condition, business strateg ...

Financial Data and Key Metrics Changes - Total revenues for Q2 2021 were $21.7 million, up 4% from $20.9 million in Q1 2021 and up 11% from $19.5 million in Q2 2020, marking a new record high for quarterly revenues [37] - Gross margin increased to 37.7% in Q2 2021 from 35.6% in Q1 2021 and 24% in Q2 2020, driven by operating leverage and lab efficiency improvements [40] - Net loss for Q2 2021 was $15 million, compared to a net loss of $9.3 million in Q2 2020, with a net loss per share of $0.34 [43] Business Line Data and Key Metrics Changes - Revenue from the oncology business grew 72% year-over-year in Q2 2021, with new orders exceeding revenue for the quarter [8][9] - Biopharma and other customer revenues (excluding VA MVP) accounted for $8.2 million in Q2 2021, representing a 6% sequential increase and a 72% increase year-over-year [37] - VA MVP revenue was $13.5 million in Q2 2021, up 2% from Q1 2021 but down 8% from Q2 2020 [39] Market Data and Key Metrics Changes - The VA MVP aims to enroll 2 million veterans, with a current enrollment rate of about 100,000 veterans per year, which could take another 10 to 12 years to achieve [28] - The VA's proposed fiscal year 2022 budget includes $802 million for medical and prosthetic research, indicating a year-over-year increase of more than 13% [29] Company Strategy and Development Direction - The company plans to expand its liquid biopsy offerings with the launch of NeXT Personal, aimed at tracking changes in specific patients' tumors [12] - The strategy focuses on supporting drug development at the leading edge of cancer biology, leveraging both tissue and liquid biopsy analyses [10][11] - The company is investing in building its regulatory and clinical capabilities to pursue business in the cancer diagnostics market [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future revenue growth due to a strong backlog and increasing orders for prospective clinical trials [9] - The company anticipates that its oncology revenue will become a larger part of total revenue as it ramps up liquid biopsy offerings [11] - Management highlighted the importance of the VA MVP as a long-term commitment, with expectations for continued funding and support [81][83] Other Important Information - The company has processed over 125,000 whole human genomes, aiming to exceed 150,000 by the end of 2021 [30] - The company is expanding operations in China, with plans to begin customer engagement before the end of 2021 [25][26] Q&A Session Summary Question: How's the China expansion going and any updates on population sequencing programs beyond the VA? - Management reported positive progress in China, with hiring and lab setup underway, despite travel limitations [50] - Discussions are ongoing with various groups regarding population sequencing opportunities beyond the VA [52] Question: Can you comment on the relative growth rate within the biopharma group? - Management noted strong orders in retrospective clinical trials, with prospective trials showing significant growth [56] Question: What is the reimbursement framework as the company transitions to clinical diagnostics? - Management indicated that the NeXT platform is designed to be validated for known biomarkers, which should facilitate reimbursement [76] Question: What is the confidence level regarding the VA's continued commitment to the program? - Management expressed high confidence in receiving further orders from the VA and noted strong internal support for the program [81][83] Question: How does the company plan to differentiate its products in the clinical context? - Management emphasized that the NeXT Personal product aims for superior sensitivity in cancer detection, which is a critical differentiator [98]